Ecansya (previously Capecitabine Krka)

Ecansya is a cancer medicine that is used to treat: - colon (large bowel) cancer. Ecansya is used on its own or with other cancer medicines in patients who have had surgery for stage III or Dukes’ stage C colon cancer; - metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body). Ecansya is used on its own or with other cancer medicines; - advanced gastric (stomach) cancer. Ecansya is used with other cancer medicines, including a platinum-containing cancer medicine such as cisplatin; - locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body). Ecansya is used with docetaxel (another cancer medicine) after treatment with anthracyclines (another type of cancer medicine) has failed. It can also be used on its own when treatment with both anthracyclines and taxanes (another type of cancer medicine) has failed or when further treatment with anthracyclines is not suitable for the patient. Ecansya is a ‘generic’ and a ‘hybrid’ medicine. This means that it is similar to a ‘reference medicine’, but it contains capecitabine at a new strength in addition to existing strengths. While the reference medicine, Xeloda, is available as 150 and 500 mg tablets, Ecansya is also available as 300 mg tablets. Ecansya contains the active substance capecitabine.